Merrill keeps ZymoGenetics at buy

ZymoGenetics Inc. was kept at a buy rating by Merrill Lynch analyst Hari Sambasivam on news that the company reported a lower-than-expected loss per share of $0.23 in the fourth quarter of 2005, compared to Merrill's estimate of a $0.36 per share loss. The analyst's revised earnings per share in 2006E-2007E are for losses of $2.20, $1.28 and $0.00, respectively, losses of from $1.40, $1.08 and $0.16. Shares of the Seattle pharmaceutical company were down 14 cents, or 0.66%, at $21.11 on volume of 453,079 shares versus the three-month running average of 455,572 shares. (Nasdaq: ZGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.